Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Triptorelin

Decapeptyl, Trelstar, Gonapeptyl, Pamorelin

Quick Stats
Studies 178
Trials 100
Score 2
2021 pubmed 3 citations

The phenotype and rhGH treatment response of ring Chromosome 15 Syndrome: Case report and literature review.

Chen. Meiping M; Ke. Xiaoan X; Liang. Hanting H; Gong. Fengying F; Yang. Hongbo H; Wang. Linjie L; Duan. Lian L; Pan. Hui H; Cao. Dongyan D; Zhu. Huijuan H

Key Findings

  • The patient had ring chromosome 15 syndrome with severe short stature and other health issues.
  • Six months of combined triptorelin and recombinant human growth hormone increased her height by 3.8 cm and boosted growth velocity.
  • Literature review supports that growth hormone treatment is beneficial for short stature in ring chromosome 15 syndrome.

Practical Outcomes

  • For biohackers, the study suggests that adding a GnRH analogue to growth hormone may give a modest extra boost in height for rare genetic short‑stature cases, but it’s not a proven, widely applicable protocol. Dosages and long‑term safety weren’t detailed, so caution and medical supervision are essential.

Summary

A young girl with a rare chromosome 15 ring disorder and very short stature was given a hormone called triptorelin (a GnRH analogue) together with growth hormone for six months. She grew about 3.8 cm, and her yearly growth rate went up, showing that this combo can help height in this specific genetic condition. The authors also reviewed other cases and found growth hormone generally helps these patients.

Abstract

Ring chromosome 15 [r (15)] is an uncommon finding with various clinical manifestations. A common phenotype for these patients has not been established and data on the efficacy of recombinant human growth hormone (rhGH) treatment in patients with r (15) syndrome are limited. One short stature patient in our hospital with r (15) syndrome by whole exome sequencing (WES) and karyotype examination was included. All published r (15) syndrome cases as of March 15, 2021, were searched, and their clinical information was recorded and summarized. One 11.5-year-old female with prenatal and postnatal growth retardation, ventricular septal defect, intellectual disability, downward corners, short fifth metacarpal bone, scattered milk coffee spots, and a right ovarian cyst was included. Her height was 126.9 cm (-3.45 SDS). Karyotype analysis showed 46, XX, r (15). WES revealed a 4.5 Mb heterozygous deletion in the chromosome 15q26.2-q26.3 region, encompassing genes from ARRDC4 to OR4F15. Gonadotrophin-releasing hormone analogue (triptorelin) and rhGH were administered for 6 months. The height has increased 3.8 cm (+0.2SDS) and the calculated growth rate has improved from 4.7 to 7.6 cm/y. The literature review indicated the main clinical manifestations of r (15) syndrome with prenatal and postnatal growth retardation, characteristic craniofacial features, and multisystem abnormalities, and rhGH treatment is beneficial for r (15) syndrome patients with short stature. We delineate the clinical spectrum of r (15) syndrome with the identification of an additional individual and rhGH treatment is beneficial for r (15) syndrome patients with short stature.

Study Information

Provider

pubmed

Year

2021

Date

2021-11-08T00:00:00.000Z

DOI

10.1002/mgg3.1842

Citations

3

References

39